MOUNTAIN VIEW, Calif., June 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will participate in two investment conferences during the month of June.
The conference presentation schedule is as follows:
Bank of America Merrill Lynch Specialty Pharmaceuticals One-on-One Conference | |
June 16, 2011 | |
Presenter: Dr. Barbara Troupin, senior director, medical affairs | |
Boston Harbor Hotel, Boston, MA | |
2011 Wells Fargo Securities Healthcare Conference | |
June 22, 2011 at 10:45 a.m. ET | |
Presenter: Timothy Morris, chief financial officer | |
The InterContinental Boston, Boston, MA | |
A live audio webcast and 30-day archive of the presentation at the 2011 Wells Fargo Securities Healthcare Conference will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has completed its phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: | |||
VIVUS, Inc. | Investor Relations: | The Trout Group | |
Timothy E. Morris | Brian Korb | ||
Chief Financial Officer | bkorb@troutgroup.com | ||
650-934-5200 | 646-378-2923 | ||
SOURCE VIVUS, Inc.
